Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease.
Ricardo Apátiga-PérezLuis O Soto-RojasB Berenice Campa-CórdobaNabil Itzi Luna-ViramontesElvis CuevasIgnacio Villanueva-FierroMiguel Angel Ontiveros-TorresMarely Bravo-MuñozPaola Flores-RodríguezLinda Garcés-RamirezFidel de la CruzJosé Francisco Montiel-SosaMar Pacheco-HerreroJose Luna-MuñozPublished in: Metabolic brain disease (2021)
Alzheimer's disease (AD) is clinically characterized by a progressive loss of cognitive functions and short-term memory. AD patients present two distinctive neuropathological lesions: neuritic plaques and neurofibrillary tangles (NFTs), constituted of beta-amyloid peptide (Aβ) and phosphorylated and truncated tau proteins. Aβ deposits around cerebral blood vessels (cerebral amyloid angiopathy, CAA) is a major contributor to vascular dysfunction in AD. Vascular amyloid deposits could be early events in AD due to dysfunction in the neurovascular unit (NVU) and the blood-brain barrier (BBB), deterioration of the gliovascular unit, and/or decrease of cerebral blood flow (CBF). These pathological events can lead to decreased Aβ clearance, facilitate a neuroinflammatory environment as well as synaptic dysfunction and, finally, lead to neurodegeneration. Here, we review the histopathological AD hallmarks and discuss the two-hit vascular hypothesis of AD, emphasizing the role of neurovascular dysfunction as an early factor that favors vascular Aβ aggregation and neurodegeneration. Addtionally, we emphasize that pericyte degeneration is a key and early element in AD that can trigger amyloid vascular accumulation and NVU/BBB dysfunction. Further research is required to better understand the early pathophysiological mechanisms associated with NVU alteration and CAA to generate early biomarkers and timely treatments for AD.